These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 20357796)

  • 1. Trial watch: NeuroSearch's dopaminergic stabilizer improves movement disorders in Huntington's disease.
    Nat Rev Drug Discov; 2010 Apr; 9(4):260. PubMed ID: 20357796
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and safety of the dopaminergic stabilizer Pridopidine (ACR16) in patients with Huntington's disease.
    Lundin A; Dietrichs E; Haghighi S; Göller ML; Heiberg A; Loutfi G; Widner H; Wiktorin K; Wiklund L; Svenningsson A; Sonesson C; Waters N; Waters S; Tedroff J
    Clin Neuropharmacol; 2010; 33(5):260-4. PubMed ID: 20616707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pridopidine for the treatment of Huntington's disease.
    Shannon KM
    Expert Opin Investig Drugs; 2016; 25(4):485-92. PubMed ID: 26881734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-lasting improvement following (-)-OSU6162 in a patient with Huntington's disease.
    Tedroff J; Ekesbo A; Sonesson C; Waters N; Carlsson A
    Neurology; 1999 Oct; 53(7):1605-6. PubMed ID: 10534281
    [No Abstract]   [Full Text] [Related]  

  • 5. A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease.
    Huntington Study Group HART Investigators
    Mov Disord; 2013 Sep; 28(10):1407-15. PubMed ID: 23450660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial.
    de Yebenes JG; Landwehrmeyer B; Squitieri F; Reilmann R; Rosser A; Barker RA; Saft C; Magnet MK; Sword A; Rembratt A; Tedroff J;
    Lancet Neurol; 2011 Dec; 10(12):1049-57. PubMed ID: 22071279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. L-acetyl-carnitine in Huntington's disease: double-blind placebo controlled crossover study of drug effects on movement disorder and dementia.
    Goety CG; Tanner CM; Cohen JA; Thelen JA; Carroll VS; Klawans HL; Fariello RG
    Mov Disord; 1990; 5(3):263-5. PubMed ID: 2143808
    [No Abstract]   [Full Text] [Related]  

  • 8. Therapeutic experience with transdihydrolisuride in Huntington's disease.
    Bassi S; Albizzati MG; Corsini GU; Frattola L; Piolti R; Suchy I; Trabucchi M
    Neurology; 1986 Jul; 36(7):984-6. PubMed ID: 2940475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pridopidine: Overview of Pharmacology and Rationale for its Use in Huntington's Disease.
    Waters S; Tedroff J; Ponten H; Klamer D; Sonesson C; Waters N
    J Huntingtons Dis; 2018; 7(1):1-16. PubMed ID: 29480206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pridopidine paradox in Huntington's disease.
    Reilmann R
    Mov Disord; 2013 Sep; 28(10):1321-4. PubMed ID: 23847099
    [No Abstract]   [Full Text] [Related]  

  • 11. Donepezil for Huntington's disease.
    Fernandez HH; Friedman JH; Grace J; Beason-Hazen S
    Mov Disord; 2000 Jan; 15(1):173-6. PubMed ID: 10634264
    [No Abstract]   [Full Text] [Related]  

  • 12. Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study.
    Reilmann R; McGarry A; Grachev ID; Savola JM; Borowsky B; Eyal E; Gross N; Langbehn D; Schubert R; Wickenberg AT; Papapetropoulos S; Hayden M; Squitieri F; Kieburtz K; Landwehrmeyer GB; ;
    Lancet Neurol; 2019 Feb; 18(2):165-176. PubMed ID: 30563778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined nitoman-pimozide treatment of Huntington's chorea and other hyperkinetic syndromes.
    Fog R; Pakkenberg H
    Acta Neurol Scand; 1970; 46(2):249-51. PubMed ID: 4246984
    [No Abstract]   [Full Text] [Related]  

  • 14. Lithium therapy in Huntington's chorea and tardive dyskinesia.
    Dalén P
    Lancet; 1973 Jan; 1(7794):107-8. PubMed ID: 4118636
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacologic approaches to the treatment of Huntington's disease.
    Venuto CS; McGarry A; Ma Q; Kieburtz K
    Mov Disord; 2012 Jan; 27(1):31-41. PubMed ID: 21997232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopaminergic manipulations and its effects on neurogenesis and motor function in a transgenic mouse model of Huntington's disease.
    Choi ML; Begeti F; Oh JH; Lee SY; O'Keeffe GC; Clelland CD; Tyers P; Cho ZH; Kim YB; Barker RA
    Neurobiol Dis; 2014 Jun; 66():19-27. PubMed ID: 24561069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tetrabenazine in the treatment of hyperkinetic movement disorders.
    Kenney C; Jankovic J
    Expert Rev Neurother; 2006 Jan; 6(1):7-17. PubMed ID: 16466307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathophysiology and therapeutic strategies in Huntington's chorea.
    Waddington JL; Cross AJ
    Lancet; 1980 Jul; 2(8187):206-7. PubMed ID: 6105376
    [No Abstract]   [Full Text] [Related]  

  • 19. Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders.
    Guay DR
    Am J Geriatr Pharmacother; 2010 Aug; 8(4):331-73. PubMed ID: 20869622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Huntington's disease and minocycline.
    Hödl AK; Bonelli RM
    Mov Disord; 2005 Apr; 20(4):510-511. PubMed ID: 15806589
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.